The Lancet publishes Lundbeck Vyepti study

The firm’s study of migraine treatment Vyepti has been published in the top-ranking medical journal, which is a stamp of approval for Lundbeck’s research quality, according to Head of R&D Johan Luthman.
Photo: Lundbeck / PR
Photo: Lundbeck / PR
by marketwire, translated by daniel pedersen

The Lancet, a top-ranking medical journal, has published results from pharmaceutical firm Lundbeck’s Deliver study of migraine drug Vyepeti, the firm announced in a press release on Thursday.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading